This week in IPOs: three exchanges, three allocation mechanisms
Holtec prices on Nasdaq, NSE India opens for subscription, and Ligent debuts in Hong Kong — one week, three different ways to allocate an IPO.
Three IPOs are converging on trading debuts within days of each other this week, on three different exchanges, and each is allocating shares to investors by a genuinely different mechanism. Holtec Nuclear is finishing a US-style bookbuild on Nasdaq. The National Stock Exchange of India opened its own listing to public subscription today under India's tiered bidding process. And Ligent Technologies is closing a Hong Kong offering built around a cornerstone-investor tranche. Same week, same basic goal — sell shares to the public for the first time — three structurally different paths to get there.
Holtec Nuclear: the US bookbuild, nearly done
Holtec Nuclear launched its roadshow on September 8, offering 50 million Class A shares in a $15–$18 range — up to $900 million at the top of the range, against a targeted $10.2 billion valuation on listing under ticker HNUC. J.P. Morgan, Guggenheim Securities, Goldman Sachs, Citigroup and BofA Securities lead a nine-bank syndicate, with pricing and a trading debut expected around September 18. That's the standard US mechanism: a roadshow where the underwriting banks build an order book from institutional investors over one to two weeks, set a final price based on that demand, and allocate shares almost entirely at the banks' discretion. The underwriters also hold a 30-day option to buy up to 7.5 million additional shares at the IPO price — the greenshoe, explained in more detail here — which exists specifically to let them stabilize the stock if it trades down right after listing. Once HNUC actually starts trading, it'll show up in Zorro's tracker of recently priced IPOs alongside every other US listing from the past three months.
NSE India: anchor day, then three public tranches
The National Stock Exchange of India Limited set its own IPO price band at ₹1,700–₹1,785 per share and opened anchor investor bidding today, September 16 — one day ahead of the public offer, which runs September 17 to 21. Allotment is expected September 22, with listing on the BSE targeted for September 24. The whole offering is a pure offer-for-sale of roughly 126.4 million shares (about ₹22,562 crore, or roughly $2.5 billion) from existing holders including LIC, SBI and Temasek — no new shares, no primary capital raised.
The mechanism is where it diverges sharply from Holtec's. Indian IPOs run a mandatory anchor tranche a day before the public book opens: a fixed group of institutional investors gets allocated shares at a price set that morning, subject to its own lockup, before retail and other institutional investors ever see the book. The public offer itself is then split into fixed statutory buckets — a portion reserved for qualified institutional buyers, a portion for non-institutional investors, and a portion for retail, each subscribing separately and each getting allotted by a pro-rata or lottery formula within its own bucket rather than by banker discretion. A US roadshow lets underwriters allocate to whoever they think will hold the stock; India's structure allocates by statute before demand is even known. Anyone tracking where NSE sits in the broader IPO pipeline can watch that anchor-to-listing sequence play out over the next eight days.
Ligent Technologies: cornerstone investors lock in the deal first
Ligent Technologies, the Hisense-controlled optical-communications maker, is running a third distinct model in Hong Kong. Its offering of roughly 172 million shares at HK$32.96 each — about HK$5.45 billion, or $695–727 million depending on the source — closes to public subscription this week, with a trading debut set for September 22. Before that book ever opened, close to 30 cornerstone investors, including Primavera, GigaDevice, Amlogic, Mirae Asset Securities, PAG, Barings, GF Fund and E Fund, had already agreed to collectively buy about 47% of the shares on offer, at the same price the public will pay.
Cornerstone commitments are negotiated and signed before the deal is marketed at all — they're a Hong Kong- and Singapore-market fixture that a US bookbuild doesn't really have an equivalent for. The trade-off is a lockup: cornerstone shares typically can't be sold for six months after listing, which is exactly the kind of restriction our lockup-expirations piece walks through — a chunk of nearly half of Ligent's float will already be spoken for through mid-March 2027 before a single public share trades. Ligent's own numbers back up why almost 30 institutions wanted in that early: first-half 2026 revenue rose 27.7% to 5.39 billion yuan (about $803 million), with roughly 70% of that coming from the datacom transceivers that plug into AI data-center networks.
Why the mechanism is worth tracking, not just the price
None of these three differences changes what a share of HNUC, NSE, or Ligent is actually worth once it's trading — a bookbuild, an anchor tranche, and a cornerstone commitment are all just different ways of answering the same question of who gets allocated stock and at what price before the open. But they carry different signals worth reading correctly. A heavily anchored or cornerstoned deal front-loads a known set of long-term holders and a known lockup calendar, which can mean thinner early liquidity than a comparably sized US bookbuild produces. A US greenshoe gives underwriters a specific, time-limited tool to support the price in week one that neither the Indian nor Hong Kong structure replicates in the same form. None of that is a reason to expect one listing to trade better than another — it's a reason to read the allocation structure before assuming every IPO pop or wobble means the same thing.